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Background/Aims. Pancreatic ductal adenocarcinoma (PDA) has etiological association with chronic inflammation. Elevated circu-
lating levels of inflammatory mediators, such as monocyte chemoattractant protein-1 (MCP-1), are found in obese individuals.
We hypothesized that serum MCP-1 levels are elevated in obese PDA patients. Methods. ELISA was used to analyze MCP-1 serum
levels in PDA (n = 62) and intraductal papillary mucinous neoplasms (IPMN) (n = 27). Recursive partitioning statistical analysis
investigated the relationship between log MCP-1 and clinicopathological parameters. Results. Log MCP-1 values were significantly
(P < 0.05) elevated in patients with BMI ≥ 37.5. In patients with BMI < 37.5, average log MCP-1 values were significantly elevated
in PDA patients when compared to IPMN patients. Within the IPMN group, higher log MCP-1 levels correlated with increased
age. Recursive partitioning analysis of IPMN versus PDA revealed a strategy of predicting characteristics of patients who are more
likely to have cancer. This strategy utilizes log MCP-1 as the primary factor and also utilizes smoking status, gender, and age.
Conclusion. MCP-1 is a promising biomarker in pancreatic cancer. The potential of using MCP-1 to distinguish PDA from IPMN
patients must be studied in larger populations to validate and demonstrate its eventual clinical utility.
1. Introduction
With an estimated 35, 420 deaths in 2008, pancreatic cancer
is the fourth leading cause of cancer death in the United
States [1]. Pancreatic cancer has an overall five-year survival
rate of only 4%, as fewer than 10% of patients’ tumors are
confined to the pancreas at the time of diagnosis. In most
cases, the cancer has progressed to the point where surgical
resection is impossible. In a disease that is still considered
most often incurable, there remains a need for new strategies
for prevention and novel methods for early diagnosis.
One factor that is believed to have an important role in
the development of pancreatic cancer is obesity. Obesity is
defined as a body mass index (BMI) > 30, and in the United
States, more than 30% of the population is classified as obese
[2]. Several studies have shown that the adipose tissue is an
active source of inflammatory mediators, suggesting that
obesity causes a chronic, low-level inflammatory state [3].
This is thought to contribute to the development of many
of the comorbidities found in obese patients, such as athe-
rosclerosis, diabetes, and cancer [4, 5]. This concept is sup-
ported by studies that have observed altered chemokine levels
and deceased cancer mortality rates with weight loss or in
morbidly obese patients that have undergone bariatric sur-
gery [6, 7]. The mediators of chronic inflammation, such as
cytokines, free oxygen radicals, and chemokines, can cause
cellular injury, DNA damage, and increased proliferation,
creating a microenvironment in which carcinogenesis is fa-
vored [8, 9].
One of the key chemokines involved in the initiation
of inflammation is monocyte chemoattractant protein-1
(MCP-1). MCP-1 triggers chemotaxis and transendothelial
migration of monocytes by interacting with their membrane
CC (have two adjacent cysteine amino acids near their amino
terminus) chemokine receptor 2 (CCR2) [10, 11]. In squa-
mous cell carcinoma of the esophagus, MCP-1 expression
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Table 1: Clinicopathological characteristics of PDA patients and MCP-1 levels.
PDA n = 62 % MCP-1 (pg/mL) mean ± SEM P value Survival at 12 months P value
Average age (yrs) 64.7
<60 (mean 52.9) 20 211.1 ± 68.37 0.12 83% 0.9
>60 (mean 70.2) 42 232.91 ± 51.69 74%
M 28 45 209.1 ± 50.5 0.9 85% 0.5
F 34 55 239.7 ± 62.9 67.9%
BMI
Normal weight (<25) 20 32 174.3 ± 30.7 77.7%
Overweight (25–29.9) 28 45 227.8 ± 55.3 0.09 75.7% 0.08
Obese (>30) 14 23 277.5 ± 141 71.3%
AJCC stage
I 5 8 69.12 ± 22.04 80%
II 46 74 228.43 ± 35.5 0.62 75% 0.4
III-IV 11 18 104.52 ± 15.6 62%
Grade
G1 8 13 280.15 ± 119.6 83%
G2 37 60 186.99 ±102.63 0.34 80% 0.5
G3-G4 17 27 302.63 ± 38.82 65%
Lymph nodes
N0 7 11 106.08 ± 30.37 83%
N1-N2 16 26 155.04 ± 26.77 80%
N3-N5 17 27 321.82 ± 85.19 0.07 63% 0.06
>N6 22 36 241.16 ± 91.066 50%
in cancer cells was correlated with venous invasion, distant
metastasis, and lymph node metastasis [12]. In addition,
MCP-1 was demonstrated to act as a potent chemotactic fac-
tor for myeloma cells [13, 14]. MCP-1 gene transfer has been
shown to enhance the metastatic potential of cancer cells
with increased neovascularization [15]. To date, most studies
in cancer have focused on MCP-1 tissue expression while
only a few have investigated the clinical utility of its serum
level measurements. With the exception of a few publications
on cervical and ovarian cancers [16, 17], which showed a cor-
relation between MCP-1 systemic levels and cancer progres-
sion, no studies have evaluated MCP-1 serum levels in corre-
lation with PDA risk factors, such as obesity. This, in associa-
tion with other known pancreatic cancer risk factors, such as
age and smoking, may contribute to predicting which patient
population is more at risk to develop pancreatic cancer [18].
In this study, we investigated the relationship between
increased body weight and BMI in pancreatic cancer patients
and the circulating levels of MCP-1. We also evaluated
whether MCP-1 serum levels could serve as diﬀerentiation
marker for benign and malignant lesions. In this respect
we examined MCP-1 serum levels in PDA patients and in
patients with benign IPMNs.
2. Materials and Methods
2.1. Patients. This retrospective study included 89 patients
with pancreatic lesions who underwent pancreatic resection.
Blood was collected by venous puncture prior to surgery
from patients who underwent surgical resection at Thomas
Jeﬀerson University Hospital between 2005 and 2008. Serum
samples were prepared and stored at −80◦C until analyzed.
Sixty-two patients had pathologically confirmed invasive
PDA, and twenty-seven had intraductal papillary mucinous
neoplasms (IPMNs). Clinical data were obtained from
Thomas Jeﬀerson University Hospital electronic medical re-
cords and from patients charts. All patients signed an ap-
propriate consent form. The study was approved by the
Institutional Review Board at Thomas Jeﬀerson University.
Clinical data, tumor characteristics, and AJCC staging of
these patients are shown in Table 1.
2.2. Methods. Serum concentrations of MCP-1 were mea-
sured using commercially available human MCP-1-specific
enzyme-linked immunosorbent assays (ELISAs) (R&D Sys-
tems, Minneapolis, MN) according to the manufacturer’s
protocol. Spectrophotometric evaluation of MCP-1 levels
was analyzed by Synergy HT multidetection Microplate
reader (BioTeck, Winooski, VT).
2.3. Statistical Analysis. Multivariable logistic regression
analysis was used to determine the association of clinical
factors and the protein MCP-1 with pancreatic cancer status.
MCP-1 protein expression was analyzed first as raw levels
then in a logarithmic scale, in order to achieve a symmetric
distribution. An assessment of sensitivity and specificity of
the multivariable logistic regression model was completed
using receiver-operating characteristic (ROC) methods. As
an alternative approach, recursive partitioning analysis was
used in two ways, first to demonstrate the relationship
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Table 2: Clinicopathological characteristics of IPMN patients and MCP-1 levels.
IPMN N = 27 % MCP-1 (pg/mL) mean ± SEM P value
Average age (yrs) 66.6
<60 (mean 53.3) 9 33 87.9±17.6 0.09
>60 (mean 72.8) 18 67 142.7± 17.7
M 7 26 152.9 ± 21.9 0.12
F 20 74 113.9 ± 14.3
BMI
Normal weight (<25) 10 37 80 ± 14.1
Overweight (25–29.9) 10 37 150 ± 17.7 0.34
Obese (>30) 7 26 132 ± 30
of MCP-1 with demographic and clinical characteristics,
and second to demonstrate the overall diﬀerences between
demographic, clinical, and MCP-1 characteristics of patients
with pancreatic cancer and patients with benign pancreatic
lesions (IPMNs). Sensitivity and specificity of the resulting
algorithm to determine cancer versus benign pathology was
completed using the standard definitions of these measures.
A linear mixed model was used to compare mean values of
MCP-1 across defined subgroups from the recursive parti-
tioning model. Linear contrasts of the least squares means
were used to compare across recursive-partitioning defined
subgroups. No adjustment for multiple comparisons was
made to the P values. Probabilities ≤ 0.05 were considered
significant. Analysis was completed using R version 2.9.2 and
SAS version 9.2 (SAS; Campus Drive, Cary, NC).
3. Results
3.1. Patient Characteristics. The patients’ data and clinico-
pathological parameters are summarized in Table 1. The av-
erage age at diagnosis was 64.7 years (range 41 to 80 years)
for PDA patients and 66.6 years (44–81 years) for IPMNs
patients. The average duration of followup was 15.2 months
(range, 1.5–31 months). BMI was calculated as weight in
kilograms divided by the square height in meters, based on
the patient’s preoperative admission data. The National
Heart, Lung, and Blood Institute’s definition for overweight
and obesity was used to classify the patients by their weight.
A BMI < 18.5 was classified as underweight; a BMI between
18.5 and 24.9 was classified as normal weight; a BMI between
25.0 and 29.9 was classified as overweight; a BMI > 30 was
classified as obese. Themean BMI for all patients in this study
was 26.6 kg/m2. Values of MCP-1 in pg/mL in each group are
seen in Tables 1 and 2.
3.2. MCP-1 Serum Levels in Obese Patients. Values forMCP-1
were logarithmically transformed prior to significance test-
ing, as their distributions were skewed. Recursive partition-
ing analysis of log MCP-1 indicates that log MCP-1 values
are elevated in patients with BMI ≥ 37.5 (average log MCP-
1 = 6.68). In patients with BMI < 37.5, elevated MCP-1
levels are seen in patients with cancer (average log MCP-1 =
4.94). In patients with benign lesions, log MCP-1 values
are elevated with age (age < 55, average log MCP-1 = 3.59;
age ≥ 55, average log MCP-1 = 4.81). Using contrasts from
the linear model, these mean diﬀerences were tested, with
results presented in Table 3.
3.3. MCP-1 Serum Levels, Patient Clinicopathological Parame-
ters, and the Presence of PDA Compared with Benign IPMN.
Recursive partitioning analysis of benign versus malignant
pathology reveals a strategy of predicting characteristics of
patients who are more likely to have cancer. This strategy
utilizes log MCP-1 as the primary factor and also utilizes
smoking status, gender, and age. The algorithm achieves 95%
sensitivity and 59% specificity. As seen in Figure 1, recursive
partitioning demonstrates that the lowest levels of logMCP-1
were obtained in benign nonobese patients under the age of
55 (log MCP-1 = 3.59). Benign nonobese patients 55 years
old and over had average log MCP-1 levels of 4.81, and
nonobese cancer patients had MCP-1 level of 4.94. Obese
patients, regardless of cancer status, had the highest level of
log MCP-1 (6.68).
3.4. MCP-1 Serum Levels and Cancer Predictability. Log
MCP-1 inmultivariate logistic regression analysis controlling
for gender, age, BMI, and quartiles of log MCP-1 was com-
pleted. As seen in Figure 2, patients within the highest quar-
tile of log MCP-1 were 6.2 times more likely to be pancreatic
cancer patients when compared to patients within the lowest
quartile of log MCP-1 (adjusted odds ratio 6.2, 95% confi-
dence interval [1.1, 37.4], P = 0.04). The ROC curve result-
ing from this model could not identify a combination that
obtained both high sensitivity and high specificity.
4. Discussion
With the rising epidemic of obesity, several studies have
revealed that the chronic inflammatory changes associated
with obesity may explain some comorbidities in obese
patients and even the increased incidence of cancer in this
patient population [19, 20]. Cytokines and chemokines and
their receptors have been analyzed in cancer patients and
animal models to attempt to elucidate this link.
Chemokines form a superfamily of small, inducible, proin-
flammatory chemotactic cytokines. These proteins have been
reported to be involved in a variety of immune and inflam-
matory responses, acting primarily as chemoattractants and
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Table 3: Subgroups of levels of log MCP-1 as defined by recursive partitioning. Data in diagonal cells represents least squares mean of the
specified subgroup, while unadjusted P values are provided in the oﬀ-diagonal cells.
BMI < 37.5,
diagnosis: benign,
age < 55
CI
BMI < 37.5,
diagnosis: benign,
age ≥ 55
CI BMI < 37.5,
diagnosis: cancer
CI BMI ≥ 37.5,
diagnosis: cancer
CI
BMI < 37.5,
diagnosis: benign,
age < 55
3.59 2.9–4.3
BMI < 37.5,
diagnosis: benign,
age ≥ 55
P = 0.003 4.81 4.5–5.1
BMI < 37.5,
diagnosis: cancer
P < 0.001 P = 0.46 4.94 4.8–5.1
BMI ≥ 37.5,
diagnosis: cancer
P < 0.001 P < 0.001 P = 0.001 6.68 5.7–7.7
BMI < 37.5 BMI ≥ 37.5
As.factor (diagn) = Bngn As.factor (diagn) = Cncr
Age < 55 Age ≥ 55
3.59
n = 5
4.81
4.94
n = 60
n = 22
6.68
n = 2
Error: 0.768 CV 1.15 SE: 0.234error:
Figure 1: Multivariate logistic regression analysis was used to deter-
mine the association of clinical factors and the protein MCP-1 with
pancreatic cancer status. An assessment of sensitivity and specificity
of this model was completed using receiver-operating characteristic
(ROC) methods. Recursive partitioning analysis was used to de-
monstrate the relationship of log MCP-1 with demographic and
clinical characteristics. The lowest levels of log MCP-1 were ob-
tained in benign nonobese patients under the age of 55 years (3.59).
Benign nonobese patients aged 55 years and over had average log
MCP-1 levels of 4.81, and nonobese cancer patients had log MCP-
1 levels of 4.94. Obese patients, regardless of cancer status, had the
highest level of log MCP-1 (6.68).
activators of specific leukocytes. MCP-1 is a member of the
C-C subfamily of chemokines and is expressed upon stimu-
lation in a wide variety of cells, such as mononuclear leuko-
cytes, fibroblasts, endothelial and epithelial cells, smooth
muscle cells, melanocytes, and various tumor cells [21].
MCP-1 is a key element of the immunological response to
malignant growth, mainly via attraction and activation of
tumor-associated macrophages [22]. The presence of high
tumor levels of MCP-1 has been reported in several malig-
nancies in relation to tumor progression [11–15]. However,
no previous studies have examined serum levels of MCP-
1 in correlation with pancreatic cancer risk factors. To our
knowledge, this is the first report (a) demonstrating a posi-
tive correlation between the level of a particular chemokine
and the subject BMI as a risk factor for PDA and (b) revealing
the potential validity of MCP-1 as a diﬀerentiation marker
for benign and malignant lesions.
Our data show that although raw value of MCP-1 did not
show significance when correlated with the diﬀerent clinico-
pathological parameters in PDA (Table 1) or IPMN patients
groups, patients with BMI≥ 37.5 averaged higher logMCP-1
values than patients with a BMI < 37.5 when using recursive
partitioning analysis. These data support the findings of
other studies showing correlation of high circulating MCP-
1 levels in obese individuals [23, 24] and in type 2 diabetes
[25]. However, previous studies have shown that serum
levels of MCP-1 are decreased after weight loss in obese
healthy individuals [24, 25]. Due to the late presentation of
pancreatic cancer, many patients may have already lost a con-
siderable amount of weight by the time they have presented
for surgical intervention. Therefore, our patients’ serum
MCP-1 levels during their peak BMI may have decreased by
the time of their pancreatic resection. Thus, based on our
present data, we cannot conclude that weight loss due to PDA
itself may be associated with reduced MCP-1 levels in PDA
patients and future studies are needed to test this hypothesis.
Our data also show that, in the less obese patients, there
was high association between elevated BMI and increased log
MCP-1 levels in PDA patients compared to the nonsignif-
icant association in patients with benign IPMNs. In those
patients with benign lesions, higher values were seen with
age >55. These findings might be independent of the benign
lesion itself, since previous studies have reported increased
circulating levels of MCP-1 with advanced age [26].
Previous studies have shown the validity of MCP-1 as a
diﬀerentiationmarker between benign andmalignant lesions
in gliomas [27] and ovarian cancer patients [28]. In our stud-
ies, using multivariate logistic regression analysis we exam-
ined MCP-1 in relation to other clinical characteristics and
risk factors to evaluate which groups had an increased rate
of PDA. First, we found that patients within the highest
quartile of log MCP-1 were 6.2 times more likely to have
pancreatic cancer than those patients within the lowest log
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< 5.057
Benign
Benign
Benign
Benign
6/2
4/21
2/22
2/6
≥ 4.402< 4.402
< 4.969≥ 4.969
Age < 77.5Age ≥ 77.5
Cancer
Cancer
Cancer
Cancer
3/92/0
2/0
6/1
Error: 0.519 CV error: 1.33 SE: 0.171
Miss class rate: null = 0.307 :model = 0.159 : CV = 0.409
Gender = female Gender =male
As. factor (smoke) = 0 As. factor (smoke) = 1
log MCP ≥ 5.272
log MCP
log MCP log MCP
log MCP log MCP
log MCP≥ 5.057
log MCP < 5.272
Figure 2: Recursive partitioning analysis was used to demonstrate the overall diﬀerences between demographic, clinical, and log MCP-1
characteristics of patients with PDA and patients with benign IPMN. Sensitivity and specificity of the resulting algorithm to determine
cancer versus benign patients was completed using the standard definitions of these measures. Word at end of node demonstrates that
the algorithm predicts either Benign or Cancer for the subgroup and graph then represents how many Benign/Cancer patients are in each
subgroup. Standard logistic regression analysis utilizing log MCP-1 could not attain this level of sensitivity and specificity combined, rather
it could achieve high values of one of these metrics at the expense of the other.
MCP-1. In the patients with the lower quartile of log MCP-1,
increased rate of cancer was seen in those with known risk
factors for pancreatic cancer, such as smoking or male sex.
It remains to be determined, however, whether MCP-1 could
serve as a comparable marker independent of the established
marker for pancreatic cancer CA 19–9. These studies that
are currently ongoing in our laboratory are important to
document the validity of MCP-1 as a possible candidate in
the ongoing eﬀorts to find adequate combined screening
systems for high risk patients and to monitor the prognosis
of PDA patients following surgical resection.
A single study has been published so far regarding the
prognostic value of MCP-1 serum levels in PDA. Christian-
sen et al. (2005) [27] reported that higher MCP-1 serum lev-
els correlate with increased macrophage infiltration of pan-
creatic cancer tissue and with a favorable prognosis and over-
all survival. However, it has also been reported that mono-
cyte/macrophage infiltration of malignant tissue may pro-
mote tumor growth by producing various chemokines [8, 9].
In our series, MCP-1 serum levels showed no clear influ-
ence on the patients’ prognosis regarding disease-free and
overall survival. Although the cellular sources of circulating
MCP-1 are not determined, our data indicate that MCP-1 is
a promising biomarker that might play a functional role in
the natural history of PDA, especially in obese patients.
4.1. Study Limitations. Since this was a pilot study, we fo-
cused only on our patients’ population. A larger study that
includes age and weight-matched healthy volunteers and a
larger number of patients is currently under preparation.
Comparative data on CA-19–9 and other markers of inflam-
mation, such as C-reactive protein, could be extremely valu-
able to determine how MCP-1 levels compare to other fac-
tors. Studies to address these deficiencies are currently ongo-
ing in our laboratory.
Because the findings of this study are limited to surgically
resected patients with PDA or IPMN, the temporal relation-
ship between MCP-1 level changes in the serum and the
progression of PDA remains unknown. The absence of sig-
nificant correlations between clinicopathological parameters
and the circulating MCP-1 levels should be interpreted with
caution. The sample size was relatively small, and our follow
up period was relatively short for association studies andmay
have mitigated against demonstrating statistical associations.
Moreover, further study of this protein in diﬀerent benign
and unresectable malignant lesions, to understand the nature
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of the relationship of its elevation with age and with highest
levels of obesity, will assist with the full development of the
potential clinical usage of this marker.
5. Conclusion
The promise demonstrated using MCP-1 plus other patient
characteristics to distinguish patients with benign versus ma-
lignant disease must be studied in larger populations to both
validate and demonstrate their eventual clinical utility.
Acknowledgment
This work was supported by NIHGrant 1R21 CA133753-02.
References
[1] American Cancer Society, Cancer Facts and Figures 2008,
American Cancer Society, Atlanta, Ga, USA, 2008.
[2] Centers for Disease Control and Prevention, “Obesity and
Overweight,” http://www.cdc.gov/obesity/index.html.
[3] J. N. Fain, “Release of interleukins and other inflammatory
cytokines by human adipose tissue is enhanced in obesity and
primarily due to the nonfat cells,” Vitamins and Hormones, vol.
74, pp. 443–477, 2006.
[4] D. S.Michaud, E. Giovannucci,W. C.Willett, G. A. Colditz,M.
J. Stampfer, and C. S. Fuchs, “Physical activity, obesity, height,
and the risk of pancreatic cancer,” Journal of the American
Medical Association, vol. 286, no. 8, pp. 921–929, 2001.
[5] E. E. Calle, C. Rodriguez, K. Walker-Thurmond, and M. J.
Thun, “Overweight, obesity, and mortality from cancer in
a prospectively studied cohort of U.S. Adults,” New England
Journal of Medicine, vol. 348, no. 17, pp. 1625–1638, 2003.
[6] R. Cancello, C. Henegar, N. Viguerie et al., “Reduction of ma-
crophage infiltration and chemoattractant gene expression
changes in white adipose tissue of morbidly obese subjects
after surgery-induced weight loss,” Diabetes, vol. 54, no. 8, pp.
2277–2286, 2005.
[7] G. H. Schernthaner, H. P. Kopp, S. Kriwanek et al., “Eﬀect of
massive weight loss induced by bariatric surgery on serum lev-
els of interleukin-18 and monocyte-chemoattractant-protein-
1 in morbid obesity,” Obesity Surgery, vol. 16, no. 6, pp. 709–
715, 2006.
[8] F. Balkwill, “Cancer and the chemokine network,” Nature
Reviews Cancer, vol. 4, no. 7, pp. 540–550, 2004.
[9] F. Balkwill and A.Mantovani, “Inflammation and cancer: back
to virchow?” Lancet, vol. 357, no. 9255, pp. 539–545, 2001.
[10] L. Gu, B. Rutledge, J. Fiorillo et al., “In vivo properties of mo-
nocyte chemoattractant protein-1,” Journal of Leukocyte Biol-
ogy, vol. 62, no. 5, pp. 577–580, 1997.
[11] E. Melgarejo, M. A. Medina, F. Sa´nchez-Jime´nez, and J. L.
Urdiales, “Monocyte chemoattractant protein-1: a key medi-
ator in inflammatory processes,” International Journal of Bio-
chemistry and Cell Biology, vol. 41, no. 5, pp. 998–1001, 2009.
[12] N. Koide, A. Nishio, T. Sato, A. Sugiyama, and S. I. Miya-
gawa, “Significance of macrophage chemoattractant protein-1
expression and macrophage infiltration in squamous cell car-
cinoma of the esophagus,” American Journal of Gastroenterol-
ogy, vol. 99, no. 9, pp. 1667–1674, 2004.
[13] I. Vande Broek, K. Asosingh, K. Vanderkerken, N. Straetmans,
B. van Camp, and I. van Riet, “Chemokine receptor CCR2
is expressed by human multiple myeloma cells and mediates
migration to bone marrow stromal cell-produced monocyte
chemotactic proteins MCP-1, -2 and -3,” British Journal of
Cancer, vol. 88, no. 6, pp. 855–862, 2003.
[14] K. Jo¨hrer, K. Janke, J. Krugmann, M. Fiegl, and R. Greil,
“Transendothelial migration of myeloma cells is increased
by tumor necrosis factor (TNF)-α via TNF receptor 2 and
autocrine up-regulation of MCP-1,” Clinical Cancer Research,
vol. 10, no. 6, pp. 1901–1910, 2004.
[15] E. Nakashima, N. Mukaida, Y. Kubota et al., “Human MCAF
gene transfer enhances the metastatic capacity of a mouse
cachectic adenocarcinoma cell line in vivo,” Pharmaceutical
Research, vol. 12, no. 11, pp. 1598–1604, 1995.
[16] A. Lebrecht, L. Hefler, C. Tempfer, and H. Koelbl, “Serum cy-
tokine concentrations in patients with cervical cancer: in-
terleukin-4, interferon-γ, andmonocyte chemoattractant pro-
tein-1,” Gynecologic Oncology, vol. 83, no. 1, pp. 170–171,
2001.
[17] L. Hefler, C. Tempfer, G. Heinze et al., “Monocyte chemoat-
tractant protein-1 serum levels in ovarian cancer patients,”
British Journal of Cancer, vol. 81, no. 5, pp. 855–859, 1999.
[18] T. P. Yeo, R. H. Hruban, J. Brody, K. Brune, S. Fitzgerald, and
C. J. Yeo, “Assessment of ”gene-environment” interaction in
cases of familial and sporadic pancreatic cancer,” Journal of
Gastrointestinal Surgery, vol. 13, no. 8, pp. 1487–1494, 2009.
[19] D. R. Cottam, S. G. Mattar, E. Barinas-Mitchell et al., “The
chronic inflammatory hypothesis for the morbidity associated
with morbid obesity: implications and eﬀect of weight loss,”
Obesity Surgery, vol. 14, no. 5, pp. 589–600, 2004.
[20] D. P. Rose, D. Komninou, and G. D. Stephenson, “Obesity,
adipocytokines, and insulin resistance in breast cancer,”
Obesity Reviews, vol. 5, no. 3, pp. 153–165, 2004.
[21] T. J. Schall, “Biology of the RANTES/SIS cytokine family,”
Cytokine, vol. 3, no. 3, pp. 165–183, 1991.
[22] E. J. Leonard and T. Yoshimura, “Human monocyte chemoat-
tractant protein-1 (MCP-1),” Immunology Today, vol. 11, no.
3, pp. 97–101, 1990.
[23] G. Murdolo, A. Hammarstedt, M. Sandqvist et al., “Monocyte
chemoattractant protein-1 in subcutaneous abdominal adi-
pose tissue: characterization of interstitial concentration and
regulation of gene expression by insulin,” Journal of Clinical
Endocrinology and Metabolism, vol. 92, no. 7, pp. 2688–2695,
2007.
[24] C. S. Kim, H. S. Park, T. Kawada et al., “Circulating levels
of MCP-1 and IL-8 are elevated in human obese subjects
and associated with obesity-related parameters,” International
Journal of Obesity, vol. 30, no. 9, pp. 1347–1355, 2006.
[25] P. Tretjakovs, A. Jurka, I. Bormane et al., “Relation of inflam-
matory chemokines to insulin resistance and hypoadiponect-
inemia in coronary artery disease patients,” European Journal
of Internal Medicine, vol. 20, no. 7, pp. 712–717, 2009.
[26] T. S. Church, M. S. Willis, E. L. Priest et al., “Obesity, macro-
phage migration inhibitory factor, and weight loss,” Interna-
tional Journal of Obesity, vol. 29, no. 6, pp. 675–681, 2005.
[27] T. Christiansen, B. Richelsen, and J. M. Bruun, “Monocyte
chemoattractant protein-1 is produced in isolated adipocytes,
associated with adiposity and reduced after weight loss in
morbid obese subjects,” International Journal of Obesity, vol.
29, no. 1, pp. 146–150, 2005.
[28] H. Inadera, K. Egashira, M. Takemoto, Y. Ouchi, and K. Mat-
sushima, “Increase in circulating levels of monocyte chemoat-
tractant protein-1 with aging,” Journal of Interferon and Cyto-
kine Research, vol. 19, no. 10, pp. 1179–1182, 1999.
